ASLAN Pharma Q2 EPS $(0.11) Beats $(0.80) Estimate, Upfront Strategic License Payment of $12.00M.
Portfolio Pulse from Benzinga Newsdesk
ASLAN Pharma (NASDAQ:ASLN) reported Q2 losses of $(0.11) per share, beating the analyst consensus estimate of $(0.80) by 86.25%. This is an 88.42% increase over losses from the same period last year. The company also reported $12.00 million in sales this quarter.
August 11, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ASLAN Pharma's Q2 results exceeded expectations, with losses per share and sales both improving significantly YoY.
ASLAN Pharma's better-than-expected Q2 results, including a significant reduction in losses per share and a solid sales figure, are likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100